drugset / Trial / NCT01254370

Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease

NCT01254370

Phase 2 Completed 105 enrolled Santen SAS
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to compare: * the effect of Catioprost® and Travatan Z® on the ocular surface disease (OSD) in subjects with glaucoma or ocular hypertension and ocular surface disease. * the intraocular pressure (IOP) lowering effect and safety of Catioprost® and Travatan Z® in subjects with glaucoma or ocular hypertension and ocular surface disease.

Timeline

Start
2010-11
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Latanoprost Small molecule 0.005 %
Comparator Travoprost Other / unclassified 0.004 %